Scinai Immunotherapeutics Ltd. (SCNI) stock
SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.75−0.00 (-0.32%)
Close on Oct 19, 2026Market cap $1.27MP/E –Yield –
Scinai Immunotherapeutics cash
Cash and short-term investments held at the end of each period.
Scinai Immunotherapeutics's cash was $2.65M at Jun 30, 2026. For fiscal 2025 it was $1.66M, down 20.7% from the year before. The highest annual figure on record is $22.54M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66M | -20.7% |
| FY2024 | Dec 31, 2024 | $2.10M | -57.0% |
| FY2023 | Dec 31, 2023 | $4.87M | -65.7% |
| FY2022 | Dec 31, 2022 | $14.22M | -18.9% |
| FY2021 | Dec 31, 2021 | $17.52M | +469.3% |
| FY2020 | Dec 31, 2020 | $3.08M | -86.3% |
| FY2019 | Dec 31, 2019 | $22.54M | +9.5% |
| FY2017 | Dec 31, 2017 | $20.59M | +354.5% |
| FY2016 | Dec 31, 2016 | $4.53M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.65M | -13.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.66M | -65.9% |
| Q2 FY2025 | Jun 30, 2025 | $989.00K | -1.1% |
| Q4 FY2024 | Dec 31, 2024 | $2.10M | -72.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.08M | -71.5% |
| Q4 FY2023 | Dec 31, 2023 | $4.87M | -65.7% |
| Q3 FY2023 | Sep 19, 2023 | $1.00M | -91.1% |
| Q2 FY2023 | Jun 30, 2023 | $7.51M | -51.2% |
| Q1 FY2023 | Mar 31, 2023 | $10.80M | -38.4% |
| Q4 FY2022 | Dec 31, 2022 | $14.22M | +32.4% |
| Q2 FY2022 | Jun 30, 2022 | $11.29M | +266.8% |
| Q1 FY2022 | Mar 31, 2022 | $15.39M | -31.7% |
| Q4 FY2021 | Dec 31, 2021 | $17.52M | -14.9% |
| Q3 FY2021 | Sep 30, 2021 | $10.74M | +137.0% |
| Q4 FY2020 | Dec 31, 2020 | $3.08M | – |
| Q4 FY2019 | Dec 31, 2019 | $22.54M | – |
| Q4 FY2017 | Dec 31, 2017 | $20.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.53M | – |
See a number that looks wrong?